

# Oklahoma Health Care Authority

## Drug Utilization Review Board (DUR Board)

Meeting – July 12, 2017 @ 4:00 p.m.

Oklahoma Health Care Authority  
4345 N. Lincoln Blvd.  
Oklahoma City, Oklahoma 73105

---

### AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

**1. Call to Order**

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

**2. Public Comment Forum**

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

**3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. June 14, 2017 DUR Minutes – Vote
- B. June 14, 2017 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Beasley, Dr. Muchmore, Chairman:

**4. Update on Medication Coverage Authorization Unit/SoonerCare Opioid Initiative Update – See Appendix B**

- A. Medication Coverage Activity for June 2017
- B. Pharmacy Help Desk Activity for June 2017
- C. SoonerCare Opioid Initiative Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**5. Action Item – Vote to Prior Authorize Austedo™ (Deutetrabenazine) and Xenazine® (Tetrabenazine) – See Appendix C**

- A. Introduction
- B. Xenazine® (Tetrabenazine) Off-Label Uses
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Update the Inhaled Tobramycin Products, Pulmozyme® (Dornase Alfa), and Cayston® (Aztreonam) Prior Authorization Criteria – See Appendix D**

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Ingrezza™ (Valbenazine) – See Appendix E**

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**8. Action Item – Vote to Update the Atypical Antipsychotic Prior Authorization Criteria and Tier Chart – See Appendix F**

- A. Introduction
- B. College of Pharmacy Recommendations
- C. Recommended Prior Authorization Criteria

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**9. Action Item – Vote to Prior Authorize Carac® (Fluorouracil 0.5% Cream), GoNitro™ (Nitroglycerin Sublingual Powder), Soltamox® (Tamoxifen Citrate Oral Solution), Taytulla™ (Norethindrone Acetate/Ethinyl Estradiol Capsules & Ferrous Fumarate Capsules), Tirosint®-SOL (Levothyroxine Sodium Oral Solution), Xatmep™ (Methotrexate Oral Solution), Zovirax® (Acyclovir Ointment and Suspension), Xerese® (Acyclovir/Hydrocortisone Cream), & Denavir® (Penciclovir Cream) – See Appendix G**

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nichols, Dr. Muchmore, Chairman:

**10. Action Item – Vote to Prior Authorize Aczone® (Dapsone Gel) and Tazorac® (Tazarotene Cream and Gel) – See Appendix H**

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**11. Action Item – Vote to Prior Authorize Vyvanse® (Lisdexamfetamine Chewable Tablets) and Update the ADHD Prior Authorization Criteria and Tier Chart – See Appendix I**

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**12. 30-Day Notice to Prior Authorize Radicava™ (Edaravone) – See Appendix J**

- A. Introduction
- B. Market News and Updates
- C. Radicava™ (Edaravone) Product Summary
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

**13. Annual Review of Atopic Dermatitis (AD) Medications and 30-Day Notice to Prior Authorize Eucrisa™ (Crisaborole 2% Ointment), Dupixent® (Dupilumab Injection), & Prudoxin™ and Zonalon® (Doxepin 5% Cream) – See Appendix K**

- A. Current Prior Authorization Criteria
- B. Utilization of AD Medications
- C. Prior Authorization of AD Medications
- D. Market News and Updates
- E. Eucrisa™ (Crisaborole 2% Ointment) Product Summary
- F. Dupixent® (Dupilumab Injection) Product Summary
- G. Prudoxin™ and Zonalon® (Doxepin 5% Cream) Product Summary
- H. College of Pharmacy Recommendations
- I. Utilization Details of AD Medications

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

**14. 30-Day Notice to Prior Authorize Vimizim® (Elosulfase Alfa) – See Appendix L**

- A. Introduction
- B. Vimizim® (Elosulfase Alfa) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**15. Annual Review of Natpara® (Parathyroid Hormone Injection) and 30-Day Notice to Prior Authorize Rayaldee® (Calcifediol), Parsabiv™ (Etelcalcetide), Zemplar® (Paricalcitol Capsules), and Hectorol® (Doxercalciferol Capsules) – See Appendix M**

- A. Current Prior Authorization Criteria
- B. Utilization of Parathyroid Medications
- C. Prior Authorization of Natpara®, Calcimimetics, and Vitamin D Analogs
- D. Market News and Updates
- E. Product Summaries

- F. College of Pharmacy Recommendations
- G. Utilization Details of Calcimimetics and Vitamin D Analogs
- H. Utilization Details of Natpara® (Parathyroid Hormone Injection)

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**16. Annual Review of Opioid Analgesics and Opioid Medication Assisted Treatment (MAT) Medications & 30-Day Notice to Prior Authorize Arymo™ ER (Morphine Sulfate Extended-Release), Troxyca® ER (Oxycodone/Naltrexone Extended-Release), Vantrela™ ER (Hydrocodone Extended-Release), Oxaydo® (Oxycodone), and RoxyBond™ (Oxycodone) – See Appendix N**

- A. Current Prior Authorization Criteria
- B. Utilization of Opioid Analgesics and MAT Medications
- C. Prior Authorization of Opioid Analgesics & MAT Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Opioid Analgesics
- H. Utilization Details of MAT Medications

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**17. 30-Day Notice to Prior Authorize Brineura™ (Cerliponase Alfa) – See Appendix O**

- A. Introduction
- B. Market News and Updates
- C. Brineura™ (Cerliponase Alfa) Product Summary
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**18. Annual Review of Antidepressants and 30-Day Notice to Prior Authorize Marplan® (Isocarboxazid) and Desyrel® (Trazodone 300mg Tablets) – See Appendix P**

- A. Current Prior Authorization Criteria
- B. Utilization of Antidepressants
- C. Prior Authorization of Antidepressants
- D. Market News and Updates
- E. Marplan® (Isocarboxazid) Product Summary
- F. Cost Comparison
- G. College of Pharmacy Recommendations
- H. Utilization Details of Antidepressants

Items to be presented by Dr. Nichols, Dr. Muchmore, Chairman:

**19. Annual Review of Fibric Acid Derivative Medications and 30-Day Notice to Prior Authorize Choline Fenofibrate Delayed-Release (Trilipix®) 135mg Capsules and Fenofibrate Micronized (Lofibra®) 200mg Capsules – See Appendix Q**

- A. Current Prior Authorization Criteria
- B. Utilization of Fibric Acid Derivative Medications
- C. Prior Authorization of Fibric Acid Derivative Medications
- D. Market News and Updates
- E. Cost Comparison
- F. College of Pharmacy Recommendations
- G. Utilization Details of Fibric Acid Derivative Medications

Non-Presentation; Questions Only:

**20. Annual Review of Fibromyalgia Medications – See Appendix R**

- A. Current Prior Authorization Criteria
- B. Utilization of Fibromyalgia Medications
- C. Prior Authorization of Fibromyalgia Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Fibromyalgia Medications

Non-Presentation: Questions Only:

**21. Annual Review of Ocaliva® (Obeticholic Acid) – See Appendix S**

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Ocaliva® (Obeticholic Acid)
- D. Prior Authorization of Ocaliva® (Obeticholic Acid)
- E. Market News and Updates
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**22. Industry News and Updates – See Appendix T**

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

**23. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix U**

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**24. Future Business\* (Upcoming Product and Class Reviews)**

*No meeting scheduled for August 2017.*

- A. Synagis® (Palivizumab)
- B. Growth Hormone
- C. Fabrazyme® (Agalsidase Beta)
- D. Allergy Immunotherapies
- E. Breast Cancer
- F. Hemophilia Medications
- G. Insomnia Medications
- H. Alzheimer's Medications
- I. Anticoagulants & Platelet Aggregation Inhibitors

*\*Future business subject to change.*

**25. Adjournment**